{"name":"Inge Marie Svane","slug":"inge-marie-svane","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADP-TILIL7","genericName":"ADP-TILIL7","slug":"adp-tilil7","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ADP-TILIL7","genericName":"ADP-TILIL7","slug":"adp-tilil7","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQVWJiQ1RzNmRxVVoxOG0tay1yVGFrblZMUXV1NVZkTGp6b29qdzZwXzFsbUFoWS1SMTJsdl9ocTVuUTRCOUVWb3M4MV9HN2NPTlhIaWs5TU1na0dkUUNrVHc1LU5uZEIzU2dnRjNIQVQzaHRwYjFMS3N0MUgwalpBYlUtREE5RXBLX2IxSmF6YUYzZHhBS3FzUmFESDc2aW5ZdDdIMzBUMXNWZmg2alU0?oc=5","date":"2025-11-03","type":"pipeline","source":"pharmaphorum","summary":"ESMO25: Immuno-therapies and translational research in oncology, with Inge Marie Svane - pharmaphorum","headline":"ESMO25: Immuno-therapies and translational research in oncology, with Inge Marie Svane","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQb3JGRVZVQWJ4dVJ1ZTY0bFlEWEVsY2dQMWdxdVJJQW1uZGZLRFBuVmVveUxwclpzdlZwaTNxRXZYclpvcTdQZnNhdFZ2b2VsbjQycWRxQUtBWGtWTzhPUnZQZm9IdWJ5YVc1SG9PODFpNk5rTEg4TV9XUC1nQlN5bGVGbjhqNWh5eng1RnVYdVNxdWlXWFNnQ3hUczhmVWxUX1E4?oc=5","date":"2024-06-03","type":"pipeline","source":"Pharma Voice","summary":"Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old - Pharma Voice","headline":"Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBjT2k1d1U2aGc1Z0xLSFF6eFZxQ1REYzNmLU1zbFJuTXZWTVhVQ3VKSUpnR3dvUmdmMzdxSHNMa2p1QndHaGk1aE4zN1llX1M3S1hDR3pucDJZVm9VVlNV?oc=5","date":"2021-12-09","type":"trial","source":"Nature","summary":"A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma - Nature","headline":"A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPeVU5dHRLSFJyX0owaXNDWGlJMjRsZ1F5XzN2b1ZqdzYxTDRoYVRXc0dXb0NKZEJIWlZZVjNBMWp5aFg0SGk0NHduUUhqV0JwU2NLeDVTWFJZR1FGTE1XTVVQZjl6QXQ5RlBfRVVKZTVWRXprenB1WDNhRmhlQ1U1OTcyS1dzZEZDOW90Qkhlbkd3dVlaZWl1cHZJdDhtYm8?oc=5","date":"2021-05-18","type":"pipeline","source":"Oncology Nursing News","summary":"TIL Therapy May Be the Curative Answer for Metastatic Melanoma - Oncology Nursing News","headline":"TIL Therapy May Be the Curative Answer for Metastatic Melanoma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}